Health & Wellness

Press Releases

Atlantic Health System Cancer Care First in World to Begin Clinical Trial of Novel Virus-Based Immunotherapy for Late-Stage Melanoma; First Patient Enrolled


Dr. Eric Whitman Leads Study of Experimental Drug That Uses Cold Virus to Disable Cancer Cells in Patients Who Have Not Responded to Other Treatments

Morristown, NJ Atlantic Health System Cancer Care is the first oncology institution in the world to sign on to, and to enroll the first patient in, a multicenter Phase IIa clinical trial of OBP-301 (Telomelysin®), a virus-based immunotherapy for late-stage melanoma that has not responded to other treatments. 

This leading-edge experimental therapy, which is under development by Japanese biotechnology company Oncolys BioPharma, uses the common cold virus to modify a gene that can selectively replicate in, and destroy, cancer cells. The study protocol was approved by the U.S. Food and Drug Administration (FDA) in June.

Sign Up for E-News

The clinical trial is being led locally by Eric D. Whitman, MD, FACS, medical director of Atlantic Health System Cancer Care and director of the Carol G. Simon Cancer Center’s Atlantic Melanoma Center at Morristown Medical Center and Overlook Medical Center.

“This targeted immunotherapy holds great promise for improving survival rates in patients with unresectable and metastatic melanoma,” said Dr. Whitman.  “We are proud to have been chosen as the first site for this leading edge clinical trial, and happy to be able to offer a wide range of the latest established and experimental treatments to our patients.”

Melanoma, the most serious form of skin cancer, affects more than 50,000 people each year. Although the chances of having melanoma increase with age, the number of cases among young adults is rising every year. Melanoma can have serious health consequences and may even be fatal.

The OBP-301 trial is a multicenter, Phase IIa study to evaluate how melanoma tumors respond to injection of this drug in patients with Stage III and Stage IV melanoma -- that is, to determine how much the drug shrinks or destroys tumors after it is injected into them.  The study, which will also look at potential side effects, is “open label,” meaning that all participants in the study will receive OBP-301. 

OBP-301 is a type of virus known as an adenovirus. Adenoviruses are common in nature and when they multiply in normal human cells they may cause infections that result in symptoms like those of the common cold or the flu.  OBP-301 has been genetically changed from the original virus to reproduce in target cancer cells that are emitting a certain signal. As a result of this reproduction, OBP-301 is believed to burst and kill tumor cells.

Study participants will receive multiple injections into their tumors over a period of several weeks.  Blood tests will be done to evaluate the level of virus in patients’ systems, and for immune response monitoring. Dr. Whitman and colleagues will also evaluate how long it takes to get a response and how long responses last, as well as overall survival and progression-free survival rates.

In preclinical studies, Oncolys demonstrated OBP-301’s anti-tumor activity in various types of cancer cells.  A Phase I clinical trial in the U.S. demonstrated the drug’s safety, and showed that it shrank tumors in a majority of study participants, who had a variety of solid tumors.  Additional studies of the drug have been completed, or are underway, in Japan, Korea and Taiwan.

The Atlantic Melanoma Center, a clinical and research center of excellence, is an internationally-recognized program. The center’s multidisciplinary approach-- combining the expertise of board-certified surgeons, medical oncologists, pathologists, radiation oncologists and nurses – treats all forms of melanoma, including those in the skin, mucous membranes and eyes.  Patients receive the latest medical treatments, and when needed, melanoma surgery is also available. 

For more information on the OBP-301 clinical trial or other studies, please call the Atlantic Melanoma Center at 973-971-7111.  

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News


Businesses Celebrate Success at the Morris County EDC Awards Luncheon

March 19, 2018

PARSIPPANY, NJ - Over 220 business executives gathered to celebrate the successes of the Morris County businesses that were recognized at the Morris County Economic Development's annual awards luncheon.  This year's event was held at the Wyndham/Hamilton Park Conference Center and featured a Keynote address from William DeRosa, Chief of Oncology at Summit Medical Group Cancer ...

Pine Brook Massage Parlor Shut Down After Several Failed Inspections

March 19, 2018

MONTVILLE, NJ – A used prophylactic in the trash, apparent “table showers,” and the implication of employees sleeping and cooking in the Swan Lake Spa massage parlor in Pine Brook resulted in the spa’s license revocation at a hearing held by the Board of Health March 12.

The spa had been in business on Route 46 since 2012 and had been subject to a revised 2012 ordinance ...

Local Boy Scouts Invite Alumni to Gathering on March 19th

March 17, 2018

Were you a Cub Scout?  Did you earn the rank of Eagle Scout? Maybe you served as a volunteer at one point? Then this is the event for you.  All former Scouts and vounteers are welcome to attend the  Black River District Alumni Gatheirng. The event is hosted by the Patriots’ Path Council Alumni Committee and being held on Monday, March 19 at 7:00 pm at the Rockaway River Barn ...

Upcoming Events

Thu, March 22, 5:00 PM

The Mansion at Mountain Lakes, Mountain Lakes

St. Mary's Prep Tricky Tray

Food & Drink

Sat, March 24

Black Diamond Billiard's, Union

Ladies 9-Ball Pro-Am by the Garden State Pool Tour

Other Sports

'Trying' explores age, youth and points of history in poignant production

‘Trying’ explores youth, age and points of history in poignant production

By Liz Keill

NEW BRUNSWICK, NJ – The George Street Playhouse presents an engrossing, two-character play based on the real life of Francis Biddle, former Attorney General.

Biddle, a Harvard educated lawyer, served under Franklin Roosevelt and later Harry Truman during the Nuremberg Tribunal. His ...


AtlantiCast: Episode 13

On this episode of AtlantiCast, new clinical studies in the fields of cardiology and immunotherapy, national and statewide recognitions for Atlantic Health System medical centers and the inaugural AtlantiCast Collab Challenge!


In Cold Blood by Truman Capote

In Cold Blood by Truman Capote (Random House, 1965)


In Cold Blood is, quite simply, the grand-daddy of true crime writing, dubbed by Capote, himself, as the first non-fiction novel (although Norman Mailer argued the point when he published The Executioner's Song in 1979.) The conditions under which I read In Cold Blood for the first time were pretty weird, which was another ...

Ian Hockley Visits New Jersey to Introduce Program to Empower Youth

This week I am taking a departure from book reviewing to share an important program that has been introduced to New Jersey this week by Mr. Ian Hockley, founder of the Dylan's Wings of Change Foundation. On December 14, 2012, Hockley's five year old son, an autistic child named Dylan, was gunned down in his classroom in the Sandy Hook Elementary School shooting. Dylan, a shy and adorable ...